Shots: The filling is based on the results of P-III IMpassion130 study, assessing Tecentriq + Abraxane vs PBO + Abraxane in 902 patients with 1L unresectable LA/M TNBC in ratio (1:1) P-III IMpassion130 study results: mPFS (7.2 vs 5.5mos.); OS (25.0 vs 15.5mos.); no new safety signals, Presented at ESMO 2018. The expected FDA approval […]Read More
